Jagsonpal Pharmaceuticals: SEBI Takeover Disclosure filed under Regulation 31(4)

M&A / JV 30 Jun 2026 · Filed / open· ✓ Verified

Jagsonpal Pharmaceuticals Limited, a publicly listed pharmaceutical company, has filed a disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with the NSE. This filing is a mandatory disclosure requirement when a person or group proposes to acquire shares that would result in substantial control or when crossing the 25% shareholding threshold. The precise acquirer identity, consideration structure, and target shareholding percentage are not disclosed in the NSE filing header.

Why it mattersRegulation 31(4) disclosure signals either a pre-bid announcement by an acquirer or a material shareholder crossing the 25% threshold; the filing initiates the formal takeover timeline under SEBI SAST, requiring open offer mechanics and board approval scrutiny.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals